PUK1 INCIDENCE AND COST OF ADVERSE EVENTS (AES) IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) TREATED WITH ANGIOGENESIS INHIBITORS (AIS)

Autor: L. Antras, Duh, E Dial, D. Rodermund, Maureen P. Neary, TK Choueiri, William Oh

Publikováno v: Value in Health. 13(3)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d53a2f4e7d9e37c072454d91e88be1ab

Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma.

Autor: TK Choueiri¹, BI Rini¹, JA Garcia¹, RC Baz¹, RM Abou-Jawde¹, SG Thakkar¹, P Elson¹, TM Mekhail¹, M Zhou², RM Bukowski¹

Publikováno v: Annals of Oncology. Feb2007, Vol. 18 Issue 2, p249-255. 7p.

Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial.

Autor: Grünwald V; Interdisciplinary Genitourinary Oncology, Clinic for Urology, Clinic for Medical Oncology, University Hospital Essen, Essen, Germany., McKay RR; Division of Hematology-Oncology, University of California San Diego, La Jolla, California, USA., Buchler T; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic., Eto M; Department of Urology, Kyushu University, Fukuoka, Japan., Park SH; Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Takagi T; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan., Zanetta S; Department of Oncology, Georges-François Leclerc Cancer Centre, Dijon, France., Keizman D; Department of Oncology, Tel-Aviv Sourasky Medical Center and School of Medicine, Tel-Aviv University, Tel-Aviv, Israel., Suárez C; Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Négrier S; University of Lyon, Centre Léon Bérard, Lyon, France., Lee JL; Department of Oncology and Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea., Santini D; Department of Medical Oncology A, Policlinico Umberto 1, La Sapienza Università di Roma, Rome, Italy., Bedke J; Department of Urology and Transplantation Surgery, Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany., Staehler M; Department of Urology, University Hospital of Munich, Munich, Germany., Kollmannsberger C; Department of Medical Oncology, BC Cancer - Vancouver Cancer Centre, Vancouver, British Columbia, Canada., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Burgents JE; Global Clinical Development, Merck & Co., Inc., Rahway, New Jersey, USA., Xie R; Biostatistics, Eisai Inc., Nutley, New Jersey, USA., Okpara CE; Clinical Research, Eisai Ltd., Hatfield, UK., Powles T; Department of Oncology, The Royal Free NHS Trust, London, UK.

Publikováno v: International journal of cancer [Int J Cancer] 2024 Dec 30. Date of Electronic Publication: 2024 Dec 30.

Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.

Autor: Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org., Porta C; University of Bari 'A. Moro' and Policlinico Consorziale, Bari, Italy., Eto M; Kyushu University, Fukuoka, Japan., Hutson TE; Texas Tech University Health Science Center, Dallas, TX, USA., Rha SY; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Merchan JR; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA., Winquist E; Western University, London, Ontario, Canada., Gurney H; Macquarie University, Sydney, NSW, Australia., Grünwald V; University Hospital Essen, Essen, Germany., George S; Roswell Park Cancer Institute, Buffalo, NY, USA., Markensohn J; Merck & Co., Inc., Rahway, NJ, USA., Burgents JE; Merck & Co., Inc., Rahway, NJ, USA., Cristescu R; Merck & Co., Inc., Rahway, NJ, USA., Sachdev P; Eisai Inc., Nutley, NJ, USA., Narita Y; Eisai Co., Ltd., Ibaraki, Japan., Huang J; Eisai Inc., Nutley, NJ, USA., Zhao Z; Eisai Inc., Nutley, NJ, USA., Okpara CE; Eisai Ltd., Hatfield, UK., Minoshima Y; Eisai Co., Ltd., Ibaraki, Japan., Choueiri TK; Dana-Farber Cancer Institute, Boston, MA, USA.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Dec 11. Date of Electronic Publication: 2024 Dec 11.

Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial.

Autor: Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu., Kuzel TM; Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, IL, USA., Tykodi SS; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Verzoni E; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Kluger H; Section of Medical Oncology, Yale Cancer Center, New Haven, CT, USA., Nair S; Department of Hematology/Oncology, Lehigh Valley Topper Cancer Institute, Allentown, PA, USA., Perets R; Division of Oncology, Clinical Research Institute at Rambam, Rambam Health Care Campus, Technion - Israel Institute of Technology, Haifa, Israel., George S; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Gurney H; Department of Clinical Medicine, Macquarie University, Sydney, NSW, Australia., Pachynski RK; Siteman Cancer Center, Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA., Folefac E; Department of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Castonguay V; Department of Medicine, CHU de Quebec -Université Laval, Quebec City, Quebec, Canada., Lee CH; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Vaishampayan U; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA., Miller WH Jr; Segal Cancer Centre and Lady Davis Institute, Jewish General Hospital, Montréal, Quebec, Canada; Department of Oncology, McGill University, Montréal, Quebec, Canada., Bhagavatheeswaran P; Department of Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ, USA., Wang Y; Department of Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ, USA., Gupta S; Department of Translational Medicine Oncology, Bristol Myers Squibb, Princeton, NJ, USA., DeSilva H; Department of Global Drug Development, Bristol Myers Squibb, Princeton, NJ, USA., Lee CW; Department of Clinical Trials, Bristol Myers Squibb, Princeton, NJ, USA., Escudier B; Department of Medical Oncology, Gustave Roussy, Villejuif, France., Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Publikováno v: ESMO open [ESMO Open] 2024 Dec; Vol. 9 (12), pp. 104073. Date of Electronic Publication: 2024 Dec 05.